Antivirals-Lecture #2
Quiz yourself by thinking what should be in
each of the black spaces below before clicking
on it to display the answer.
Help!
|
|
||||
---|---|---|---|---|---|
show | 3TC
🗑
|
||||
2. T/F The molecular compound of Lamivudine is? | show 🗑
|
||||
3. T/F The brand names for Lamivudine are Zeffix, Heptovir, Epivir, and Epivir-HBV. | show 🗑
|
||||
4. What is the MOA of Lamivudine? | show 🗑
|
||||
show | Used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV.
🗑
|
||||
show | True
🗑
|
||||
7. T/F Combination of zidovudine with lamivudine slows development of zidovudine resistance. | show 🗑
|
||||
8. T/F Long term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus (YMDD) mutant. | show 🗑
|
||||
show | concurrent administration with TMP/SMX increases bioavailability of lamivudine
🗑
|
||||
10. What are the ADR of Lamivudine? | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
13. T/F The combination of a sugar and an heterocyclic base is a nucleoside. When a phosphate is added to the molecule, a nucleotide is created. | show 🗑
|
||||
show | d4T
🗑
|
||||
15. T/F The molecular compound of Stavudine is? | show 🗑
|
||||
show | analog of thymidine that converts to triphosphate form
🗑
|
||||
17. T/F When administering Stavudine, the Intracellular phosphorylation inhibited by AZT prevents co-administration. | show 🗑
|
||||
show | Inhibits reverse transcriptase and DNA polymerase
🗑
|
||||
19. T/F Stavudine Penetrates the blood-brain barrier. | show 🗑
|
||||
show | peripheral neuropathy, renal toxicity
🗑
|
||||
21. What should be taken with caution with the drug Stavudine? | show 🗑
|
||||
show | ddC, Hivid
🗑
|
||||
23. T/F The molecular compound of Zalcitabine is? | show 🗑
|
||||
show | It is a nucleoside analog reverse transcriptase inhibitor (NARTI)
🗑
|
||||
25. T/F Zalcitabine is sold under the trade name Hivid. | show 🗑
|
||||
26. What is the MOA of Zalcitabine? | show 🗑
|
||||
27. T/F In Zalcitabine, competitive inhibitor of dCTP is for the active site of viral reverse transcriptase. | show 🗑
|
||||
show | Inhibits viral and cellular DNA synthesis.
🗑
|
||||
29. How potent is Zalcitabine? | show 🗑
|
||||
show | Zalcitabine
🗑
|
||||
31. What is ADR of Zalcitabine? | show 🗑
|
||||
32. What does Zalcitabine cause? | show 🗑
|
||||
show | True
🗑
|
||||
show | Serum amylase levels
🗑
|
||||
35. What is the normal range of serum amylase level? | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
38. What is the tradename for Didanosine? | show 🗑
|
||||
39. T/F The molecular compound of Didanosine is 2',3'-dideoxyinosine. | show 🗑
|
||||
40. What is the MOA Didanosine? | show 🗑
|
||||
show | Not recommended for initial treatment of HIV, best for AZT-resistant HIV
🗑
|
||||
show | True
🗑
|
||||
43. How are the chewable tablets of Didanosine? | show 🗑
|
||||
44. What does the buffering compound of Didanosine cause? | show 🗑
|
||||
45. T/F New Videx EC (trade name for Didanosine) formulations uses smaller capsule containing coated microspheres instead of using a buffering compound. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | The half-life in plasma is only 1.5 hours, but 12 hours in the intracellular environment.
🗑
|
||||
50. How is Didanosine eliminated? | show 🗑
|
||||
51. What is the ADR for Didanosine? | show 🗑
|
||||
52. When administering Didanosine, what drug does it interfere? | show 🗑
|
||||
53. What is the trade name for Tenofovir? | show 🗑
|
||||
54. T/F Tenofovir is also available in a fixed-dose combination with emtricitabine in a product with the brand name Truvada for once-a-day dosing. | show 🗑
|
||||
55. T/F Emtricitabine, which is marketed in combination with Tenofovir that makes Truvada, is also marketed as a single compound product called Emtriva, also by Gilead. | show 🗑
|
||||
56. What can Tenofovir cause? | show 🗑
|
||||
show | It increases didanosine and Atazanavir concentration protease inhibitors
🗑
|
||||
show | Protease inhibitors (PIs) target viral assembly by inhibiting the activity of the HIV-1 protease.
🗑
|
||||
show | True
🗑
|
||||
60. In Protease Inhibitors, target HIV-1 protease is essential for? | show 🗑
|
||||
61. T/F HIV protease cleaves nascent proteins for final assembly of new virons. | show 🗑
|
||||
62. What are the Protease Inhibitor Agents? | show 🗑
|
||||
show | Reversibly inhibit the proteinase that is essential for the final step of viral proliferation HIV Protease in the fully open conformation, about to bind a protease inhibitor
🗑
|
||||
64. What is the trade name for Saquinavir? | show 🗑
|
||||
65. T/F Invirase is a poorly-absorbed hard gel capsule which quickly led to viral resistance in many of the pioneer patients. | show 🗑
|
||||
66. T/F Fortovase was a soft gel capsule reformulated for improved bioavailability, which now superseded by Invirase + ritonavir. | show 🗑
|
||||
show | Oral administration with high fat meals to maximize absorption
🗑
|
||||
show | True
🗑
|
||||
69. T/F Ritonavir inhibits the cytochrome P450 3A4 enzyme. | show 🗑
|
||||
70. T/F When Saquinavir is administered with co-administration delavirdine (an NNRTI), the plasma levels increase. | show 🗑
|
||||
show | headache, fatigue, nausea, diarrhea, loose stools, abdominal discomfort, increased LFT’s
🗑
|
||||
show | Crixivan
🗑
|
||||
73. T/F Indinavir is well-absorbed orally, and is the least protein bound of all of the protease inhibitors. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
77. What are the ADR for Indinavir? | show 🗑
|
||||
78. What is the tradename for Ritonavir? | show 🗑
|
||||
79. T/F Ritonavir is no longer utilized as a single PI agent due to excessive side effects. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
82. T/F Ritonavir is an inhibitor of cytochrome P450 3A4 enzymes. | show 🗑
|
||||
show | nausea, vomiting, diarrhea, asthenia, headache, circumoral paresthesia, elevated aminotransferase and triglyceride levels, taste alteration
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | diarrhea, nausea, flatulence, rash
🗑
|
||||
show | It is a Prodrug for amprenavir
🗑
|
||||
90. T/F Fosamprenavir slows conversion to amprenavir, which leads to long plasma half-life & permits twice daily dosing (reduced # pills). | show 🗑
|
||||
91. T/F Fosamprenavir offers no clinical advantage over other protease inhibitors. | show 🗑
|
||||
show | nausea, diarrhea, vomiting, oral and perioral paresthesia, rash
🗑
|
||||
show | Protease inhibitors can be used as anti-protozoals (against malaria and Giardia) and as anti-cancer Agents.
🗑
|
||||
show | True
🗑
|
||||
95. What does the Non-nucleoside reverse transcriptase inhibitors (nNRTI) inhibit? | show 🗑
|
||||
show | True
🗑
|
||||
97. T/F Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTI) has no effect on 1-nucleoside triphosphatesm or 2-human DNA polymerases. | show 🗑
|
||||
show | Major advantages are the there is a lack of cross-resistance with nucleoside reverse transcriptase inhibitors and there is a lack of effect on the host blood cell precursors
🗑
|
||||
show | 1-Atevirdine, 2-Bishetero.arylpiperazine*, 2-Delavirdine, 3-Nevirapine, 4-Efavirenz
🗑
|
||||
show | NVP, Viramune
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
103. What is the ADR of Nevirapine? | show 🗑
|
||||
show | True
🗑
|
||||
105. T/F Nevirapine increases the metabolism of protease inhibitors, which adjusts dosages. | show 🗑
|
||||
show | Increases metabolism of oral contraceptives, ketoconazole, metronidazole, warfarin, quinidine, theophylline
🗑
|
||||
107. T/F Delavirdine has efficacy that is lower than other NNRTIs, especially efavirenz, and has an inconvenient schedule, which is why it is omitted from initial therapy. | show 🗑
|
||||
show | True
🗑
|
||||
109. T/F Delavirdine is extensively plasma protein bound, and the absorption is not affected by the presence of food. | show 🗑
|
||||
110. T/F The complex set of drug interactions make the place of Delavirdine in second-line and salvage therapy is unclear, that is why it’s rarely used. | show 🗑
|
||||
show | True
🗑
|
||||
show | rash, nausea, dizziness, Headache
🗑
|
||||
113. T/F Delavirdine is an inhibitor of drug metabolism. | show 🗑
|
||||
show | Fluoxetine and ketoconazole
🗑
|
||||
115. What drugs decrease plasma levels of delavirdine? | show 🗑
|
||||
116. What is the trade name of Efavirenz? | show 🗑
|
||||
117. T/F Efavirenz is indicated for initial therapy of HIV-1. | show 🗑
|
||||
118. How is the dosing for Efavirenz? | show 🗑
|
||||
show | True
🗑
|
||||
120. What is lamivudine/zidovudine called? | show 🗑
|
||||
121. What is tenofovir/emtricitabine called? | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | dizziness, headache, loss of concentration, vivid dreams, rash
🗑
|
||||
show | Inducer of cytochrome P-450
🗑
|
||||
show | True
🗑
|
||||
127. T/F Two NRTIs plus a NNRTI can be an Initial Therapy. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
130. T/F Efavirenz + zidovudine + lamivudine is one of the preferred initial regimens. | show 🗑
|
||||
show | True
🗑
|
||||
132. T/F Lopinavir boosted with ritonavir + zidovudine + lamivudine is one of the preferred initial regimens. | show 🗑
|
||||
133. T/F Lopinavir boosted with ritonavir + tenofovir + emtricitabine. is one of the preferred initial regimens. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
136. T/F Initially, monitoring performed every 4 weeks for immune status of patients. | show 🗑
|
||||
show | Every 3 Months
🗑
|
||||
show | True
🗑
|
||||
139. T/F One of the results of treatment failure is when there is failure to reach undetectable viral load after 4-6 months of treatment. | show 🗑
|
||||
140. T/F One of the results of treatment failure is when there is detection of virus after initial complete suppression of viral load (resistance). | show 🗑
|
||||
141. T/F One of the results of treatment failure is when there is persistent decline of CD4 cells or clinical Deterioration. | show 🗑
|
||||
show | Fusion Inhibitors interfere with the interactions that enable membrane fusion between the virus, or an HIV-infected cell and an uninfected cell, reducing replication (AMD-3100, FP-21399)
🗑
|
||||
show | It uses the body’s chemical messengers to stimulate an immune response (Interleukin 2, HIV-1 Immunogen, Reticulose)
🗑
|
||||
show | It interferes with binding, fusion and entry of HIV-1 to the host cell by blocking one of several targets.
🗑
|
||||
145. What are the two currently available agents in the class of Fusion? | show 🗑
|
||||
146. What do Integrase Inhibitors inhibit? | show 🗑
|
||||
show | Thalidomide, Hydroxyurea, Interferon
🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
150. What is the first drug to target the CCR5 coreceptor on the surface of the cell? | show 🗑
|
||||
151. What is the first drug in the integrase inhibitor class? | show 🗑
|
||||
152. T/F Etravirine is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) "with clear activity against some NNRTI-resistant viruses." | show 🗑
|
||||
153. T/F There are 6 things to consider when choosing the Choice of drug. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
156. T/F One of the considerations of DOC is that a few cannot be used together (ex: d4T and AZT). | show 🗑
|
||||
show | True
🗑
|
||||
158. T/F One of the considerations of DOC is that there are other combinations that are better for some people. | show 🗑
|
||||
159. T/F One of the considerations of DOC is that every drug has different advantages and disadvantages, and newer drugs are being used as first line therapy. | show 🗑
|
||||
160. T/F Regarding Inhibiting mother-child transmission, the WHO guidelines state that pregnant women should start Zidovudine (AZT) from 28 weeks or as soon as possible from that point. | show 🗑
|
||||
161. T/F Regarding Inhibiting mother-child transmission, the mother should receive single-dose Nevirapine (NVP) when entering labor. | show 🗑
|
||||
show | True
🗑
|
||||
163. T/F Regarding Inhibiting mother-child transmission, the child should be given single dose Nevirapine immediately after delivery and daily Zidovudine until one week old. | show 🗑
|
||||
show | True
🗑
|
||||
165. T/F Regarding Mother-child Transmission, in some settings, the interventions have succeeded in reducing the risk of infection from 25% to about 1%. | show 🗑
|
||||
166. T/F In HIV Treatment, the treatment with less than 3 drugs or missing doses (even one dose a week) will lead to resistance, and the combination will fail. | show 🗑
|
||||
show | True
🗑
|
||||
168. T/F In HIV Treatment, Resistance to one drug or drug combination is associated with increased likelihood of resistance to the next combination (cross-resistance) between most drugs in each class. | show 🗑
|
||||
show | True
🗑
|
||||
show | True
🗑
|
||||
171. What is the main cause of resistance? | show 🗑
|
Review the information in the table. When you are ready to quiz yourself you can hide individual columns or the entire table. Then you can click on the empty cells to reveal the answer. Try to recall what will be displayed before clicking the empty cell.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
To hide a column, click on the column name.
To hide the entire table, click on the "Hide All" button.
You may also shuffle the rows of the table by clicking on the "Shuffle" button.
Or sort by any of the columns using the down arrow next to any column heading.
If you know all the data on any row, you can temporarily remove it by tapping the trash can to the right of the row.
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Created by:
sap_213
Popular Pharmacology sets